Abstract
Although most patients with acute myeloid leukemia (AML) achieve clinical remission with induction chemotherapy, relapse rates remain high. Next-generation sequencing enables minimal/measurable residual disease (MRD) detection; however, clinical significance is limited due to difficulty differentiating between pre-leukemic clonal hematopoiesis and frankly malignant clones. Here, we investigated AML MRD using targeted single-cell sequencing (SCS) at diagnosis, remission, and relapse (n = 10 relapsed, n = 4 nonrelapsed), with a total of 310 737 single cells sequenced. Sequence variants were identified in 80% and 75% of remission samples for patients with and without relapse, respectively. Pre-leukemic clonal hematopoiesis clones were detected in both cohorts, and clones with multiple cooccurring mutations were observed in 50% and 0% of samples. Similar clonal richness was observed at diagnosis in both cohorts; however, decreasing clonal diversity at remission was significantly associated with longer relapse-free survival. These results show the power of SCS in investigating AML MRD and clonal evolution.
References
Aug 3, 2012·Proceedings of the National Academy of Sciences of the United States of America·Michael W SchmittLawrence A Loeb
Aug 31, 2012·Science Translational Medicine·Max JanRavindra Majeti
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monique TerwijnGerrit J Schuurhuis
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvie D FreemanAlan K Burnett
Feb 20, 2014·Proceedings of the National Academy of Sciences of the United States of America·M Ryan Corces-ZimmermanRavindra Majeti
Aug 26, 2015·JAMA : the Journal of the American Medical Association·Jeffery M KlcoTimothy J Ley
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Oct 16, 2015·Nature·Dan A LandauCatherine J Wu
Nov 30, 2016·Blood·Hartmut DöhnerClara D Bloomfield
Mar 18, 2017·Haematologica·Pierre HirschFrançois Delhommeau
May 30, 2017·Nature Biotechnology·Freeman LanAdam R Abate
Sep 16, 2017·Nature Reviews. Cancer·Carlo C MaleyDarryl Shibata
Jan 14, 2018·Blood·Gerrit J SchuurhuisGert J Ossenkoppele
Feb 24, 2018·Leukemia·Maja Rothenberg-ThurleyKlaus H Metzeler
Mar 31, 2018·The New England Journal of Medicine·Mojca Jongen-LavrencicPeter J M Valk
May 23, 2018·Annals of Hematology·Marius BillSebastian Schwind
Aug 9, 2018·Genome Research·Maurizio PellegrinoDennis J Eastburn
Oct 20, 2018·Nature·Jeffrey W TynerBrian J Druker
Apr 9, 2019·The Lancet Oncology·David Collingridge
May 16, 2019·Cancer Discovery·Christine M McMahonAlexander E Perl
Citations
Jun 10, 2020·Cancers·Elise AasebøMaria Hernandez-Valladares
Sep 9, 2020·Clinical and Translational Medicine·Xiaoxuan YuHui Hui
Aug 30, 2020·Cancers·Ugo TestaElvira Pelosi
Aug 23, 2020·Current Opinion in Oncology·Shristi Upadhyay BanskotaVijaya Raj Bhatt
Oct 11, 2020·International Journal of Molecular Sciences·Chiara CarrettaRossella Manfredini
Jan 26, 2021·Leukemia Research·Pamela AchaFrancesc Solé
Nov 14, 2020·Current Opinion in Hematology·Jennifer S Romer-Seibert, Sara E Meyer
Dec 6, 2020·Nature Reviews. Clinical Oncology·Satyen H GohilKenneth J Livak
Mar 7, 2021·Cancers·Pamela AchaFrancesc Solé
Feb 22, 2021·Genes, Chromosomes & Cancer·Ulrich PfistererThoas Fioretos
Apr 4, 2021·Cancers·Ramón García-Sanz, Cristina Jiménez
Apr 4, 2021·Cancer Discovery·L Nicolas Gonzalez CastroMario L Suvà
May 23, 2021·Leukemia·Caner SayginJames S Blachly
Jun 29, 2021·Biomarker Research·Lamia MadaciRégis Costello
Aug 9, 2021·Advanced Science·Xiaofang WangYangqiu Li
Aug 20, 2021·British Journal of Haematology·Nicholas C P CrossUNKNOWN A British Society for Haematology Good Practice Paper
Aug 28, 2021·Biomolecules·Nayoung KimHae-Ock Lee
Sep 10, 2021·Leukemia & Lymphoma·Shyam A PatelJonathan M Gerber
Sep 10, 2021·Frontiers in Physiology·Thomas Stiehl, Anna Marciniak-Czochra